Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmacyte Biotech Inc (NQ: PMCB )

2.120 -0.080 (-3.64%)
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,464
Open 2.140
Bid (Size) 2.100 (10)
Ask (Size) 2.140 (6)
Prev. Close 2.200
Today's Range 2.077 - 2.150
52wk Range 1.920 - 3.080
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024
PharmaCyte Biotech just reported results for the third quarter of 2024. 
Via InvestorPlace
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024
PharmaCyte Biotech just reported results for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-2.97%
-2.97%
1 Month
-14.52%
-14.52%
3 Month
-3.20%
-3.20%
6 Month
+1.31%
+1.31%
1 Year
-29.10%
-29.10%

More News

Read More
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
From PharmaCyte Biotech, Inc.
Via Business Wire
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
From Femasys Inc.
Via GlobeNewswire
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Final Results of Tender Offer
From PharmaCyte Biotech, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
From PharmaCyte Biotech, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
From PharmaCyte Biotech
Via Business Wire
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
From PharmaCyte Biotech, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
From PharmaCyte Biotech, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.